Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIa clinical trial of VTX-3232 in subjects with obesity and certain additional risk factors for cardiovascular disease

Next Previous
Trial Profile

Phase IIa clinical trial of VTX-3232 in subjects with obesity and certain additional risk factors for cardiovascular disease

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VTX 3232 (Primary)
  • Indications Cardiovascular disorders; Obesity
  • Focus Therapeutic Use

Most Recent Events

  • 14 Jan 2025 Status changed from planning to recruiting, according to a Ventyx Biosciences media release.
  • 14 Jan 2025 According to a Ventyx Biosciences media release, first subject dosed in this trial with topline data expected in H2 2025.
  • 07 Nov 2024 According to a Ventyx Biosciences media release, company expected to initiate by year-end, with topline results anticipated in H2 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top